Articles tagged with Pancreatic Cancer
Researchers identified a gene called UCP-1 that may predict the development of pancreatic cancer in people with Type 2 diabetes. The study found three distinct metabolic phases prior to diagnosis, characterized by rising blood glucose levels and changes in body fat.
Researchers have identified at least four different types of scar tissue in human pancreatic cancer, each influencing the disease in a unique way. This discovery may lead to tailor-made treatments, including immunotherapies, that target the powerful scar tissue wall protecting the cancer.
Cancer rates linked to obesity are rising faster in US young adults compared to older generations. Incidence of certain cancer types such as colorectal, uterine corpus, and pancreatic cancer has increased significantly in younger age groups.
A new 3D imaging technique has revealed that pancreatic cancers can develop in two distinct types - 'endophytic' and 'exophytic' - depending on the size of the duct. This breakthrough may lead to improved treatments for pancreatic cancers by better understanding how cancer grows.
Researchers found distinct bacteria on the tongue of early-stage pancreatic cancer patients compared to healthy individuals. The study suggests a potential link between the immune system and pancreatic cancer, paving the way for new diagnostic or preventive tools.
A new recovery pathway has been implemented to reduce hospital stays after the Whipple operation by 15 days, allowing patients with pancreatic cancer to transition more quickly to the next phase of treatment. The study found that this accelerated care did not increase complication rates and improved patient outcomes.
CKAP4, a plasma membrane protein, is released from pancreatic cancer cells in exosomes, allowing for its detection in serum. Researchers developed anti-CKAP4 monoclonal antibodies that block tumor signaling and inhibit growth, providing a potential therapeutic intervention.
A new combination blood test has been developed to detect pancreatic cancer earlier, with a detection rate of nearly 70% and a false-positive rate of less than 5%. The test uses two different sugars produced by pancreatic cancer cells and can detect subtypes that may have been missed by existing tests.
Researchers identified VISTA on immune cells infiltrating pancreatic tumors, which resisted immune checkpoint blockade drugs. The study highlights the importance of stroma and found higher expression of VISTA in pancreatic tumors compared to melanoma.
The US cancer death rate has declined by 27% since 1991, primarily due to reductions in smoking and advances in early detection and treatment. Despite this progress, socioeconomic inequalities have widened, with poorer counties experiencing a disproportionate burden of preventable cancers.
Researchers discovered a combination of a cancer vaccine with two checkpoint drugs reduced pancreatic cancer tumors in mice, indicating a possible pathway for treatment. The approach has promise for patients who are or become resistant to immunotherapy drugs after a recurrence of their tumors.
A phase I/II trial found that combining nab-paclitaxel with gemcitabine significantly improved survival rates even among patients with reduced health status. The study's results suggest alternative treatment options for patients typically underrepresented in clinical trials.
The Pancreatic Cancer Collective has awarded $7 million in grants to seven teams of top cancer researchers. The funding will support clinical studies and accelerate the translation of research findings into treatments, with the goal of improving patient outcomes for pancreatic cancer.
A team of UC San Diego researchers has received a $1 million Stand Up To Cancer grant to test drugs that block signals driving pancreatic cancer growth. The study aims to identify new therapies that can more effectively block tumor growth and metastasis.
Researchers have discovered a new compound, ancistrolikokine E3, from a Congolese rainforest vine that effectively targets and kills pancreatic cancer cells. The compound inhibits the Akt/mTOR pathway and autophagy pathway, leading to dramatic changes in cell morphology and preventing metastasis formation.
Researchers have identified a compound, ancistrolikokine E3, from the twigs of the Ancistrocladus likoko vine that kills pancreatic cancer cells when nutrients are scarce. The compound inhibits the Akt/mTOR pathway, which is responsible for the aggressive proliferation of these cancer cells.
Researchers identified TP63 as the culprit behind aggressive pancreatic cancer's addictive behavior. Suppressing its activity could lead to a tumor's demise. The study aims to understand why TP63 gets active in some patients' pancreas, with the goal of developing a treatment to improve their survival.
Research has found a strong link between adolescent weight and an increased risk of pancreatic cancer later in life. The study analyzed data from over 1.7 million Israeli adolescents and found that obesity was associated with a four-fold higher risk of pancreatic cancer, even among those who were not obese.
Researchers are investigating the link between blood clots and pancreatic tumors, which could lead to more effective treatments for patients with pancreatic cancer. The study aims to understand how blood clots form and contribute to tumor growth, potentially leading to new therapeutic approaches.
Researchers developed an antibody to block DKK3, which stimulated cancer growth and resistance to therapy. In a mouse study, the treatment significantly prolonged life and boosted immune cell infiltration.
Researchers found that patients with a non-functional IDO2 gene had more favorable outcomes when receiving radiotherapy, living cancer-free for almost twice as long. The discovery could lead to personalized treatment recommendations and improve patient survival rates.
Researchers at UNIGE and HUG discovered that mucinous tumours of the ovary and pancreas originate from embryonic germ cells that migrate to reproductive organs. These cells can mistakenly stop in other organs, leading to cancer decades later.
A new cell-based immunotherapy using 'educated killer cells' has shown promise in eradicating pancreatic cancer, including cases where tumours have spread to multiple organs. The treatment could potentially be administered to human patients without toxic side effects.
A study found that female-specific genetic mutation ATRX increases susceptibility to pancreatitis and pancreatic cancer. The research team discovered that deleting the gene in females led to increased progression to cancer, while males with the mutation experienced reduced risk of injury and progression to cancer.
A large observational study found that individuals with diabetes are at a higher risk of developing certain cancers, including colorectal and breast cancer. The study also showed that people with diabetes who are diagnosed with cancer have poorer survival rates compared to those without diabetes.
A new drug called Metavert has shown promising results in blocking pancreatic cancer growth in laboratory mice. The study also found that Metavert may prevent patients from developing resistance to currently used chemotherapies.
A study of 50,000 people found that over 80% of those with identifiable genetic risk for breast, ovarian, prostate, and pancreatic cancer are unaware they carry the gene. The findings highlight the need for effective DNA-based screening to identify high-risk individuals before a cancer diagnosis.
Researchers have developed a new blood test that can detect pancreatic cancer in its earliest stages with 96% accuracy, providing a potential breakthrough for earlier diagnosis and treatment. The test uses an antibody microarray to identify specific immune-regulatory proteins and cancer-associated antigens.
The new study reveals that different KRAS mutations have distinct effects on the KRAS protein's molecular-level function. The findings enhance understanding of cancer-causing mutations and may lead to the development of targeted drug therapies.
Researchers at University of Houston develop synthetic compound that inhibits two major pathways of pancreatic cancer. The drug, MA242, targets NFAT1 and MDM2, reducing tumor growth and progression.
The foundation grants four-year, $231,000 fellowships to support novel projects and encourage early career researchers in cancer science. The recipients are working on innovative projects such as developing T-cell receptors for immunotherapy and understanding protein modification in cancer development.
Researchers at the GW Cancer Center will develop a model to study the COMPASS complex in pancreatic cancer and possible targeted therapies. The goal is to identify molecular vulnerabilities and treat patients based on their likelihood to respond to tailored treatments.
A new study found that Cannabidiol (CBD) significantly improved the survival rate of mice with pancreatic cancer when used alongside chemotherapy. The treatment resulted in nearly tripled survival time compared to those receiving chemotherapy alone.
A study found that fitness trackers can supplement current assessments of health status and physical function, showing increased daily activity correlates with positive patient ratings and lower adverse events. Wearable devices may help predict treatment complications and enable timely interventions.
A new study published in the British Journal of Surgery found that breath analyses can identify pancreatic cancer compounds. Researchers detected 12 specific volatile organic compounds indicative of pancreatic cancer, offering potential for early detection and treatment.
Researchers discovered that pancreatic cancer cells' ability to alter their characteristics and shape affects where metastases form. The presence of E-cadherin protein controls this process, with its absence leading to lung metastases but not liver metastases.
A multidisciplinary team from UGR has developed software that can analyze heterogeneous genetic expression data to identify potential pancreatic cancer biomarkers. The new integrative system has identified 5 commonly expressed potential biomarkers and 28 novel genes that are differentially expressed in the meta-analysis.
Researchers have discovered a potential diagnostic method for pancreatic cancer in patients with early onset diabetes by analyzing blood sugar levels over time. The ENDPAC score model identifies patients at high risk of developing pancreatic cancer, providing a new way to diagnose the disease at an earlier stage.
A new study from MIT and Dana-Farber Cancer Institute found that pancreatic tumors can cause weight loss due to reduced digestive enzymes, but treatment with enzyme replacement did not improve survival. The researchers suggest a potential protective mechanism underlying this process.
Researchers found six genes with mutations that substantially increase a person's risk for pancreatic cancer, even in those without family history. The study recommends genetic testing for all pancreatic cancer patients as the new standard of care.
A new study suggests that recent-onset type 2 diabetes may be an early manifestation of pancreatic cancer. The research found a two-fold increased risk of pancreatic cancer among individuals with recent-onset diabetes compared to those with long-standing diabetes, particularly in African Americans and Latinos.
Researchers have obtained key information about proteins in single human cells, revealing molecular happenings inside a cell. The nanoPOTS technology allows for the analysis of samples that are 500 times smaller than previously possible, providing vital insights into cellular behavior.
A new study from the Keck School of Medicine of USC shows that African-Americans and Latinos who are diagnosed with diabetes after age 50 are at increased risk of developing pancreatic cancer. Late-onset diabetes may be an early sign of pancreatic cancer, providing a potential opportunity for screening.
Researchers found that PARP inhibitors, such as rucaparib, showed promise in treating pancreatic cancer in patients with BRCA mutations. In a small study, 32% of patients experienced disease control after treatment.
Researchers developed a precision-medicine approach using patient-derived organoids to predict treatment responses in pancreatic cancer. The method identified specific gene signatures that can guide the selection of chemotherapy regimens, offering hope for improved survival rates and quality of life.
Avoiding excess body weight and maintaining a stable weight in middle adulthood may help prevent several obesity-related cancers in women. High weight gain is associated with a significantly increased risk of pancreatic cancer, breast cancer, and endometrial cancer.
A phase II clinical trial suggests patients with aggressive pancreatic cancer who harbor BRCA mutations may benefit from rucaparib, a PARP inhibitor approved for ovarian cancer. The study found 32% of patients experienced a clinical benefit, including four patients with responses and two with stable disease.
A small study of adults with pancreatic cancer reveals that patients with BRCA1 or BRCA2 gene mutations have poorer overall survival rates compared to those without the mutations. However, those with BRCA1 or BRCA2 had better survival rates with platinum-based chemotherapy.
A team led by CSHL Professor Douglas Fearon found that dormant cancer cells are already in the liver before surgery, expressing MHC1 and CK19 markers. In a post-operative stress-induced state, these cells re-express markers and begin to divide, forming seeds of metastatic lesions.
A new diagnostic test developed by researchers at UC San Diego shows promise for detecting pancreatic cancer earlier. The test uses electronic chip-based system to extract exosomes directly from blood, providing results in less than an hour. The findings have the potential to detect cancer early on without invasive surgical procedures.
Pancreatic cancer researchers and clinicians will work together to build a state-wide biobank, collecting data from diverse patient groups to minimize disparities and personalize care. The goal is to develop more effective therapeutic strategies tailored to individual needs, improving survival rates and quality of life.
Research reveals that obesity suppresses the epithelial defense against cancer, allowing malignant cells to remain and develop tumors. Aspirin treatment enhances this defense mechanism, suggesting a potential role in cancer prevention.
Dr. Christian Marín-Muller developed a microRNA treatment for pancreatic cancer and founded Speratum CR, a biotech company with the goal of creating effective therapies. The company has successfully completed preclinical studies and is planning to initiate its first human trial.
The Pancreatic Cancer Collective, funded by the Lustgarten Foundation and Stand Up To Cancer, will accelerate research for pancreatic cancer patients. The initiative aims to improve diagnosis and treatments, as well as support the next generation of pancreatic cancer investigators.
Seven new grants will support studies on personalized treatments, non-invasive cancer cell killing, and early tumor detection using advanced imaging techniques. These projects aim to improve survival statistics for pancreatic cancer patients and accelerate research progress.
Researchers at UT Health San Antonio have created a novel technology that injects a modified virus into the mouse pancreas with pro-cancer molecules, resulting in human-like tumors. This breakthrough could lead to new insights into pancreatic cancer initiation and progression, as well as spur new drug development.
Research highlights the connection between diet, obesity, and various types of cancer, including breast, colorectal, and pancreatic cancers. Dietary interventions like calorie restriction and low-fat diets may help reduce obesity-related cancer risk.
A study found that bacterial composition differs in patients with pancreatic ductal adenocarcinoma, promoting immune suppression and tumor growth. Eliminating certain bacteria slowed cancer progression and increased T-cell infiltration into tumors.
Research found that gut bacteria dominate in patients with pancreatic cancer, preventing immune system attacks on tumor cells. Antibiotics slowed cancer growth and reprogrammed immune cells to recognize cancer cells again.
The non-profit organization Destroy Pancreatic Cancer is funding a new clinical trial designed by Dr. Daniel D. Von Hoff at the Piedmont Cancer Institute, aiming to improve treatment options for pancreatic cancer patients. The trial will enroll up to 25 patients and is part of TGen's efforts to find a cure for this deadly disease.